VI
The startup has developed a proprietary intradermal microneedle delivery system for vaccines, designed to be painless and suitable for self-administration. This technology enhances vaccine delivery efficiency and increases preparedness against infectious disease threats by allowing healthcare professionals to utilize both proprietary and conventional vaccines with reduced dosage requirements.
Updated 3 months ago
Funding
$2.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup has developed a proprietary intradermal microneedle delivery system for vaccines, designed to be painless and suitable for self-administration. This technology enhances vaccine delivery efficiency and increases preparedness against infectious disease threats by allowing healthcare professionals to utilize both proprietary and conventional vaccines with reduced dosage requirements.